Navigation Links
AMDL Launches Expanded Distribution With 4th Round of Agreements Valued at $6.79 Million Annually for New Health & Beauty Product Line

TUSTIN, Calif., Nov. 7 /PRNewswire-FirstCall/ -- AMDL, Inc. (Amex: ADL), with operations in Shenzhen, Jiangxi and Jilin, China, through its wholly owned subsidiary Jade Pharmaceutical Inc. (JPI), which is an international biopharma company that engages in the development, manufacture and marketing of proprietary pharmaceutical and diagnostic products, announced today that JPI's subsidiary JJB has signed the fourth round of regional distribution agreements for its new anti-aging and skin care injectable product under the brand name "Goodnak." This initial product is the first in a new line of anti-aging & skin care products currently under development by JJB.

JJB has signed three new Central Region exclusive, one-year renewable Distribution and Agency Agreements that were signed between Jade Pharma's subsidiary JJB and Henan Yinji Bio-chemistry Co., Ltd. ("HYB"), Chengdu Fairyland Cosmetics Co., Ltd. and ("CFC"), Guizhou Camry Beauty Technology Co., Ltd. ("GCB"). These agreements cover the key cities in Henan, Sichuan and Guizhou Provinces that have a combined population of approximately 134.4 million people. These two separate agreements in combination, require these new distributors to purchase a minimum of US$6,790,944 of JJB's new HPH product during the one-year period of the contracts and a minimum initial order of US$4,061,250.

Frank Zheng, managing director of JPI, said this fourth round of additional distribution agreements, coupled with the previously announced agreements, puts the Company on the path to building sales of Goodnak by as much as $24 million over the next 12 months. Gary Dreher, CEO of AMDL said the Company expects to further update the market on its expansion plans in the coming weeks.

About Goodnak: Goodnak is a high quality injectable anti-aging & skin care product that contains an amalgam of various therapeutic elements including human placental histosolution ("HPH"). JPI has begun selling Goodnak, in August, through wholesale distribution channels that service high-end beauty salon and plastic surgery hospitals and or medical cosmetology institutions. Goodnak product information is available on Jade Pharma's product specific website:

About JPI: Jade Pharmaceutical through its subsidiaries JJB & YYB has access to the fastest growing pharmaceutical and consumer market in the world: China. AMDL, through its subsidiary, Jade currently manufactures large volume injectable fluids, tablets and other related products, holding licenses for 133 products. It also manufactures 107 generic, over the counter and supplemental pharmaceutical products under certified Chinese Good Manufacturing Practice (CGMP) standards.

About AMDL: More information about AMDL and its products can be obtained at

Forward-Looking Statements: This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks and uncertainties, and actual circumstances, events or results may differ materially from those projected in such forward-looking statements. The Company cautions readers not to place undue reliance on any forward-looking statements. The Company does not undertake, and specifically disclaims any obligation, to update or revise such statements to reflect new circumstances or unanticipated events as they occur.

Contact: AMDL, Inc.

Mr. Paul Knopick

AMDL Investor Relations

Direct Line: 949.707.5365

VoiceMail: 714.505.4460

Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Us TOO Launches National SEA Blue Campaign for Prostate Cancer Awareness Month
2. UPMC Health Plan Launches New Personal Health Record
3. Launches Video Contest for Young Directors
4. Academy of General Dentistry Launches Campaign to Focus on Tooth Erosion
5. Keeping Kids Healthy and Fit: The New York Kids Club Launches a Revolutionary New Fitness Program
6. Patient Advocate Foundation Launches Program to Help Uninsured Virginians with Chronic, Debilitating and Life-Threatening Illness Access Quality Healthcare
7. Mannatech Launches Phase One of New Sales and Training Tools
8. Coalition for Pulmonary Fibrosis Launches Aggressive Ad Campaign Directed at United States Congress
9. Actavis Launches Carvedilol Tablets in the U.S.
10. MedQuist Re-launches New, Improved Web Site
11. Elsevier launches new journal: Stem Cell Research
Post Your Comments:
(Date:12/1/2015)... ... December 01, 2015 , ... The Multiple System Atrophy Coalition has announced ... Multiple System Atrophy (MSA) research, timed today to coincide with Giving Tuesday 2015, a ... including their ability to work and be productive, to do simple daily activities like ...
(Date:12/1/2015)... ... December 02, 2015 , ... ClinicoEconomics and Outcomes Research ... of treatment for osteoporosis ”. , As corresponding author Dr Ankita Modi says ... with osteoporosis. Based on a large US managed care database, women aged 55 ...
(Date:12/1/2015)... ... December 01, 2015 , ... According to an ... has filed a discrimination claim against the U.S. Department of Health and Human Services, ... Care Act (ACA) plans are breaking the clause in the law prohibiting the denial ...
(Date:12/1/2015)... ... December 01, 2015 , ... Dr. Paul Vitenas, one of the ... named by MedEsthetics magazine as the Best Single Physician Practice in the nation. Dr. ... elite aesthetic physicians honored by the industry publication. , Dr. Vitenas said he ...
(Date:12/1/2015)... York, NY (PRWEB) , ... December 01, 2015 ... ... epidemic in the 1980s we have seen vast improvements in scientific research and ... made significant strides, providing increased hope and relief to those affected by HIV/AIDS. ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... 2015   MabVax Therapeutics Holdings, Inc . (OTCQB: ... has filed an Investigational New Drug Application (IND) with ... Company,s lead fully human antibody product HuMab 5B1 as ... to initiate the Phase I clinical trial early in ... The planned Phase I trial will evaluate the ...
(Date:12/1/2015)... FRANCISCO , Dec. 1, 2015  InCarda Therapeutics, ... development and commercialization of therapies for cardiovascular conditions via ... a subsidiary business in Australia . ... trial in Australia in the ... leading investigators and medical centers in Adelaide ...
(Date:12/1/2015)... , Dec. 1, 2015  The migration ... to develop shared care plans that help patients ... care plans will be digitally enabled, incorporate care ... needs and desires. They will also allow all ... patient,s health journey is optimal. That is the ...
Breaking Medicine Technology: